These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 35084268)

  • 1. Novel approaches for the development of direct KRAS inhibitors: structural insights and drug design.
    Haider K; Sharma A; Yar MS; Yakkala PA; Shafi S; Kamal A
    Expert Opin Drug Discov; 2022 Mar; 17(3):247-257. PubMed ID: 35084268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers.
    Pandey D; Chauhan SC; Kashyap VK; Roy KK
    Eur J Med Chem; 2024 Nov; 277():116771. PubMed ID: 39167893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From bench to bedside: current development and emerging trend of KRAS-targeted therapy.
    Chen Y; Liu QP; Xie H; Ding J
    Acta Pharmacol Sin; 2024 Apr; 45(4):686-703. PubMed ID: 38049578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?
    Nagasaka M; Li Y; Sukari A; Ou SI; Al-Hallak MN; Azmi AS
    Cancer Treat Rev; 2020 Mar; 84():101974. PubMed ID: 32014824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS Inhibitors- yes but what next? Direct targeting of KRAS- vaccines, adoptive T cell therapy and beyond.
    Nagasaka M; Potugari B; Nguyen A; Sukari A; Azmi AS; Ou SI
    Cancer Treat Rev; 2021 Dec; 101():102309. PubMed ID: 34715449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC).
    Parums DV
    Med Sci Monit; 2022 Nov; 28():e938746. PubMed ID: 36317327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors.
    Rathod LS; Dabhade PS; Mokale SN
    Drug Discov Today; 2023 May; 28(5):103557. PubMed ID: 36934967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches.
    Reck M; Carbone DP; Garassino M; Barlesi F
    Ann Oncol; 2021 Sep; 32(9):1101-1110. PubMed ID: 34089836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting KRAS in Colorectal Cancer.
    Wang C; Fakih M
    Curr Oncol Rep; 2021 Feb; 23(3):28. PubMed ID: 33582927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. More to the RAS Story: KRAS
    Lietman CD; Johnson ML; McCormick F; Lindsay CR
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35561303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.
    Zheng X; Luo J; Liu W; Ashby CR; Chen ZS; Lin L
    Drugs Today (Barc); 2022 Apr; 58(4):175-185. PubMed ID: 35412531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting mutated GTPase KRAS in tumor therapies.
    Fan G; Lou L; Song Z; Zhang X; Xiong XF
    Eur J Med Chem; 2021 Dec; 226():113816. PubMed ID: 34520956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in
    Jansen RA; Mainardi S; Dias MH; Bosma A; van Dijk E; Selig R; Albrecht W; Laufer SA; Zender L; Bernards R
    Proc Natl Acad Sci U S A; 2024 Feb; 121(9):e2319492121. PubMed ID: 38377196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS G12C inhibition and innate immune targeting.
    Tani T; Kitajima S; Conway EB; Knelson EH; Barbie DA
    Expert Opin Ther Targets; 2021 Mar; 25(3):167-174. PubMed ID: 33703985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Kras
    Christensen JG; Olson P; Briere T; Wiel C; Bergo MO
    J Intern Med; 2020 Aug; 288(2):183-191. PubMed ID: 32176377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting KRAS in cancer.
    Singhal A; Li BT; O'Reilly EM
    Nat Med; 2024 Apr; 30(4):969-983. PubMed ID: 38637634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting KRAS Diversity: Covalent Modulation of G12X and Beyond in Cancer Therapy.
    Kirschner T; Müller MP; Rauh D
    J Med Chem; 2024 Apr; 67(8):6044-6051. PubMed ID: 38621359
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Coupez D; Hulo P; Touchefeu Y; Denis MG; Bennouna J
    Expert Opin Biol Ther; 2021 Oct; 21(10):1325-1334. PubMed ID: 34378483
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Ceddia S; Landi L; Cappuzzo F
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012655
    [No Abstract]   [Full Text] [Related]  

  • 20. Drugging the Undruggable: Advances on RAS Targeting in Cancer.
    Molina-Arcas M; Samani A; Downward J
    Genes (Basel); 2021 Jun; 12(6):. PubMed ID: 34200676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.